Investors should monitor the outcome of the contested board election, as a shift in board composition could lead to changes in capital allocation and strategy. The upcoming 2026 clinical data readouts are critical catalysts that could validate the company's pipeline progress and influence stock performance.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 20 $24.90entry
- T+1 · 7mo ago −1.04%α −0.39% · $24.64
- T+5 · 7mo ago +2.61%α +1.70% · $25.55
- T+20 · 6mo ago −9.88%α −14.08% · $22.44
- T+60 · 4mo ago +1.73%α −5.05% · $25.33
Price Chart
REPLAYWatch the reaction play outExecutive Summary
Pacira BioSciences is advancing its 5x30 strategy with strong commercial momentum, highlighted by 6.2% year-over-year volume growth for EXPAREL and record-high gross margins. The company is entering a data-rich period with key 2026 catalysts from its pipeline. However, the annual meeting is contested, with activist investor DOMA Perpetual nominating three director candidates, challenging the board's composition and capital allocation strategy.
Key Facts
- EXPAREL achieved 6.2% year-over-year volume growth in 2025, with 8% growth in the second half.
- The company delivered record-high 2025 GAAP and Non-GAAP Gross Margins of 79% and 81%, respectively.
- Pacira returned $150 million to stockholders through share repurchases in 2025.
- The company is entering a data-rich period with key 2026 readouts expected for PCRX-201, ZILRETTA in shoulder OA, and iovera in spasticity.
- Activist investor DOMA Perpetual has nominated three director candidates, leading to a contested election at the annual meeting.
Financial Impact
The company repurchased $150 million in shares in 2025 and has a new $300 million authorization. The 5x30 strategy aims for double-digit compounded annual growth and a five-percentage point gross margin improvement by 2030.
Risk Factors
- The contested board election creates uncertainty around future strategic direction.
- The company faces potential generic competition for EXPAREL starting in 2030, despite a volume-limited settlement.
- The stock price performance in 2025 was negatively impacted by patent litigation, which could affect investor sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREC14A Filing (Primary) | 0001104659-26-044908 |
| Document: 0001104659-26-044908-index-headers.html | 0001104659-26-044908 |
| Document: 0001104659-26-044908-index.html | 0001104659-26-044908 |
| Document: 0001104659-26-044908.txt | 0001104659-26-044908 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers